1. In Vivo
  2. >>Global Vision

Surveying The Changing Multiple Sclerosis Landscape

The highly competitive multiple sclerosis market is in flux. With the US launch in October 2010 of Novartis AG's Gilenya, the first oral disease-modifying therapy for MS, patients and physicians have a more convenient once-daily therapy that looks to be as efficacious as first line injectables. But uncertainty concerning Gilenya's safety- not to mention the medicine's high price tag - means ample room exists for additional products in the MS armamentarium. To better understand how prescribers view the rapidly changing MS landscape, IN VIVO and Gerson Lehman Group conducted a survey of physicians in late January.

The highly competitive multiple sclerosis market, estimated to be $10 billion, is in flux. With the US launch in October 2010 of Novartis AG's Gilenya (fingolimod), the first oral disease-modifying therapy for MS, patients and physicians have a more convenient once-daily therapy that looks to be as efficacious as first-line injectables (the interferons and Teva Pharmaceutical Industries Ltd.'s Copaxone (glatiramer acetate). But uncertainty concerning Gilenya's safety – not to mention the medicine's high price tag – means ample room exists for additional products in the MS armamentarium. In the next two years, pharma and biotech players expect to release Phase III data on six competing products; already analysts are handicapping how the results – especially data from new orals like Teva's laquinimod and Biogen Inc.'s BG-12 -- will impact market share of not only Gilenya, but current standard-of-care agents.

To better understand how prescribers view the rapidly changing MS landscape, IN VIVO and Gerson Lehman Group launched a nine-question...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By David Wild

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By Ed Silverman

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By Marion Webb

S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.

More from In Vivo

Rising Leaders 2025: Kura Oncology’s Mollie Leoni On Setting Precedent, Not Following It

 
• By Jo Shorthouse

Kura Oncology's new chief medical officer discusses her path to leadership, the company's advancing AML pipeline, and her methodical approach to developing treatments for underserved oncology indications.

Finding The Fire: AltruBio’s Novel Approach To Autoimmune Disease

 
• By David Wild

CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.